Compare · ASTC vs RVTY
ASTC vs RVTY
Side-by-side comparison of Astrotech Corporation (DE) (ASTC) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ASTC and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $17.26B, about 1652.5x ASTC ($10.4M).
- Over the past year, ASTC is up 8.4% and RVTY is up 63.4% - RVTY leads by 55.0 points.
- ASTC has been more active in the news (10 items in the past 4 weeks vs 7 for RVTY).
- RVTY has more recent analyst coverage (23 ratings vs 0 for ASTC).
- Company
- Astrotech Corporation (DE)
- Revvity Inc.
- Price
- $4.79-7.09%
- $152.62-1.34%
- Market cap
- $10.4M
- $17.26B
- 1M return
- -23.87%
- +4.01%
- 1Y return
- +8.38%
- +63.42%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 10
- 7
- Recent ratings
- 0
- 23
Astrotech Corporation (DE)
Astrotech Corporation operates as a science and technology development and commercialization company worldwide. It operates through three segments, Astrotech Technologies, Inc. (ATI), 1st Detect Corporation (1st Detect), and AgLAB Inc (AgLAB). The ATI segment owns and licenses the AMS Technology, the platform mass spectrometry technology. The 1st Detect segment manufactures explosives and narcotics trace detectors for use at airports, secured facilities, and borders. This segment provides TRACER 1000, a mass spectrometer based explosives trace detector to replace the explosives trace detectors used at airports, cargo and secured facilities, and borders. The AgLAB segment develops AgLAB-1000, a mass spectrometer for use in the hemp and cannabis market. It also develops BreathTest-1000, a breath analysis tool to screen for volatile organic compound metabolites found in a person's breath. The company was formerly known as SPACEHAB, Inc. and changed its name to Astrotech Corporation in 2009. Astrotech Corporation was incorporated in 1984 is based in Austin, Texas.
Latest ASTC
- Director Kreps Matthew was granted 1,114 shares, increasing direct ownership by 52% to 3,264 units (SEC Form 4)
- Director Winn Charles Arch was granted 1,331 shares, increasing direct ownership by 10% to 14,431 units (SEC Form 4)
- Director Halinski John William was granted 1,331 shares, increasing direct ownership by 11% to 13,542 units (SEC Form 4)
- Director Stober Eric was granted 1,473 shares, increasing direct ownership by 7% to 21,127 units (SEC Form 4)
- Director Mcfarland Robert N was granted 1,331 shares, increasing direct ownership by 6% to 22,292 units (SEC Form 4)
- Director Wilkinson Tom was granted 1,331 shares, increasing direct ownership by 4% to 32,254 units (SEC Form 4)
- SEC Form 10-K filed by Astrotech Corporation (DE)
- Astrotech Corporation (DE) filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Astrotech Reports Fiscal Year 2026 Financial Results
- Innventure Leadership Increases Focus on Accelsius Value Creation, Implements Significant Cost Cuts, and Strengthens Board Independence
Latest RVTY
- Revvity to Present at Upcoming Investor Conferences
- William Blair initiated coverage on Revvity
- Revvity to Host Investor Day
- VP and CAO Gonzales Anita sold $13,060 worth of shares (84 units at $155.48) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)
- Revvity to Hold Earnings Call on November 3, 2026
- Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
- Officer Krakowiak Maxwell sold $235,728 worth of shares (1,631 units at $144.53) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 14,781 units (SEC Form 4)
- Officer Vohra Tajinder S sold $1,032,650 worth of shares (7,330 units at $140.88) as part of a pre-agreed trading plan, decreasing direct ownership by 52% to 6,635 units (SEC Form 4)
- UBS resumed coverage on Revvity with a new price target
- Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery